Biocept Inc. (BIOCQ)
OTCMKTS: BIOCQ · Delayed Price · USD
0.0001
0.00 (0.00%)
Apr 23, 2024, 12:00 AM EDT - Market open
Biocept Revenue
Biocept had revenue of $1.36M in the twelve months ending June 30, 2023, down -97.63% year-over-year. Revenue in the quarter ending June 30, 2023 was $589.00K, a -89.88% decrease year-over-year. In the year 2022, Biocept had annual revenue of $25.86M, a decrease of -57.78%.
Revenue (ttm)
$1.36M
Revenue Growth
-97.63%
P/S Ratio
0.00
Revenue / Employee
$27,120
Employees
50
Market Cap
103.65 USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 25.86M | -35.39M | -57.78% |
Dec 31, 2021 | 61.25M | 33.79M | 123.04% |
Dec 31, 2020 | 27.46M | 21.93M | 396.71% |
Dec 31, 2019 | 5.53M | 2.28M | 70.09% |
Dec 31, 2018 | 3.25M | -1.82M | -35.87% |
Dec 31, 2017 | 5.07M | 1.85M | 57.26% |
Dec 31, 2016 | 3.22M | 2.61M | 428.46% |
Dec 31, 2015 | 609.91K | 476.49K | 357.15% |
Dec 31, 2014 | 133.42K | -830.00 | -0.62% |
Dec 31, 2013 | 134.25K | 24.96K | 22.83% |
Dec 31, 2012 | 109.29K | 108.24K | 10,288.69% |
Dec 31, 2011 | 1.05K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
BIOCQ News
- 7 months ago - Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept's CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases - Business Wire
- 8 months ago - Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics - Business Wire
- 8 months ago - Biocept to Participate in the H.C. Wainwright Global Investment Conference - Business Wire
- 8 months ago - Biocept to Hold Business Update Conference Call on August 30, 2023 - Business Wire
- 9 months ago - Biocept Reports Second Quarter 2023 Financial Results - Business Wire
- 9 months ago - Biocept's CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer Conference - Business Wire
- 10 months ago - Biocept Announces the Passing of Board Chair M. Faye Wilson - Business Wire
- 11 months ago - Biocept Names Antonino Morales as President and Chief Executive Officer - Business Wire